Engineering of co-crystal drug molecules for pharmaceutical aerosols

药用气雾剂共晶药物分子工程

• 批准号: DP0881708
• 负责人: Prof Paul Young
• 金额: $ 20.82万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-06-02 至 2011-12-16
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0881708
• 关键词: Engineering; co; crystal; drug; molecules

This project will enable Australia to become a world leader in treatment of respiratory diseases. The Australian financial burden of respiratory diseases is currently estimated as $900m with significant impact on infrastructure (through regular clinical visits, hospitalisation and workforce loss). The global market for the treatment of COPD is currently $32 billion and is expected to increase significantly by 2010. The positioning of an Australian research as a world leader in the development of new treatments will have significant national benefit, whilst the sector will benefit for scientific advancements that arise during this project.

该项目将使澳大利亚成为呼吸系统疾病治疗的世界领导者。目前，澳大利亚呼吸道疾病的经济负担估计为9亿美元，对基础设施产生重大影响（通过定期临床就诊、住院和劳动力流失）。全球COPD治疗市场目前为320亿美元，预计到2010年将大幅增长。将澳大利亚的研究定位为开发新疗法的世界领导者将带来重大的国家利益，而该行业将受益于该项目期间出现的科学进步。